Close Menu

NEW YORK (GenomeWeb) – Biodesix said today that its has received a positive coverage decision from Aetna for its VeriStrat test for guiding therapy in patients with non-small cell lung cancer (NSCLC).

According to Biodesix, Aetna has deemed VeriStrat, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors, medically necessary for patients with advanced NSCLC whose tumors were without EGFR and anaplastic lymphoma kinase mutations.

Aetna has approximately 46 million members in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.